Aspirin for cancer chemoprevention: still a headache?
D016588:Anticarcinogenic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D001471:Barrett Esophagus / Q000150:complications; D003362:Cost-Benefit Analysis; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D018450:Disease Progression; D004938:Esophageal Neoplasms / Q000191:economics / Q000209:etiology / Q000517:prevention & control; D006689:Hodgkin Disease / Q000517:prevention & control; D006801:Humans; D008084:Lipoxygenase / Q000187:drug effects / Q000378:metabolism; D009203:Myocardial Infarction / Q000517:prevention & control; D016328:NF-kappa B / Q000187:drug effects; D009369:Neoplasms / Q000201:enzymology / Q000517:prevention & control*; D019057:Quality-Adjusted Life Years
D016588:Anticarcinogenic Agents; D016861:Cyclooxygenase Inhibitors; D016328:NF-kappa B; D008084:Lipoxygenase; D001241:Aspirin